Boeing’s Resurgent Production Fuels Optimism for Investors

After navigating years of turbulence, Boeing is methodically regaining its operational footing. The American aerospace giant delivered more aircraft in 2025 than in any year since 2018 and outpaced its primary rival in new orders. This recovery is gaining further momentum as U.S. regulators authorize increased production rates. However, the sustainability of this rebound is being tested against a backdrop of persistent and intense regulatory scrutiny.

A significant catalyst for the improved outlook is the official green light for Boeing to accelerate its manufacturing tempo. The Federal Aviation Administration (FAA) has approved an increase in the production rate for the 737 MAX program to 42 jets per month. This move is critical for the company to address its substantial order backlog and enhance cash inflows from customer deliveries.

The push for higher output extends to Boeing's wide-body segment as well. Management has outlined plans to raise production of the 787 Dreamliner to 10 aircraft per month during the course of 2026. This decision signals confidence in sustained airline demand for modern, fuel-efficient long-haul planes and in the resilience of the underlying supply chain.

For investors, such a production ramp-up typically delivers a dual benefit: it boosts free cash flow as more finished aircraft are delivered and paid for, while simultaneously reducing the commercial risk of customers canceling orders due to extended waiting periods.

Operational Turnaround Takes Hold

The 2025 fiscal year marked a definitive operational turning point for the company. Boeing delivered a total of 600 commercial aircraft, representing a substantial 72.4% increase over the prior year. The fourth quarter alone saw 160 deliveries, highlighting accelerating momentum as the year closed.

Demand indicators also showed marked improvement. The company secured 1,175 gross orders for its commercial division, surpassing European competitor Airbus in new orders for the first time since 2018. Consequently, Boeing's total order backlog swelled to 6,130 jets, providing years of visible workload and a solid foundation for its planned production increases.

Key operational metrics for 2025 include:
* Total commercial aircraft deliveries: 600 units
* Gross orders received: 1,175 jets
* 737 program deliveries: 447 aircraft
* 787 program deliveries: 88 aircraft

Should investors sell immediately? Or is it worth buying Boeing?

This combination of robust deliveries and a replenished order book has been reflected in the company's market valuation. Boeing's share price is currently trading at a two-year high, showing a gain of more than 50% year-to-date and an advance of approximately 40% over the past 30 trading days.

Regulatory Oversight Remains a Persistent Factor

Despite these operational strides, Boeing continues to operate under a microscope of regulatory oversight. The FAA recently issued a new Airworthiness Directive targeting certain 757-200 and 757-300 models, scheduled to take effect in February 2026. This action was prompted by a report concerning a crack found on an aircraft equipped with "blended winglets." Such directives routinely lead to mandatory inspections, potential retrofits, and added operational complexity for both airlines and the manufacturer.

In a separate development, findings from the National Transportation Safety Board (NTSB) have renewed attention on past safety protocols. An investigation into a fatal UPS crash involving an MD-11 revealed that Boeing had issued a service bulletin in 2011 regarding a component that later failed. At that time, the manufacturer concluded the part's failure did not pose an immediate flight safety risk. This history underscores why regulators maintain a vigilant watch on the company's processes.

For the investment thesis, this environment implies that even as production recovers, the risk of additional regulatory mandates or required modifications remains an ever-present factor capable of impacting both profit margins and project timelines.

Market Analysts Affirm the Recovery Path

The strengthened operational metrics and visible progress are now clearly influencing analyst sentiment. Research firm Bernstein has raised its price target for Boeing shares from $277 to $298, naming the stock a "Top Pick" for 2026.

This upgraded assessment is primarily based on:
* The ongoing increase in production rates for the 737 and 787 programs.
* Expectations for a significant expansion of free cash flow in the coming years.
* The regained momentum in both aircraft deliveries and new order intake.

From the analytical perspective, Boeing appears to be on a solid recovery trajectory. A substantial order backlog, rising production volumes, and improving cash flow prospects form a positive foundation, even as regulatory and safety considerations continue to accompany the company's journey, holding the potential to create setbacks at any time.